A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue (Q37241474)

19 August 2017

0 references

1 reference

title

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue (English)

1 reference

19 August 2017

0 references

1 reference

1 reference

4

Matthew Hotopf

1 reference

19 August 2017

3

Michael Sharpe

1 reference

19 August 2017

Ollie Minton

1

1 reference

19 August 2017

Alison Richardson

series ordinal

2

1 reference

19 August 2017

Patrick Stone

series ordinal

5

1 reference

19 August 2017

language of work or name

English

0 references

publication date

11 August 2008

1 reference

Journal of the National Cancer Institute

19 August 2017

1 reference

19 August 2017

100

1 reference

19 August 2017

1155-1166

1 reference

19 August 2017

16

1 reference

Fatigue in cancer patients receiving chemotherapy: an analysis of published studies

19 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Off-treatment fatigue in breast cancer survivors: a controlled comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Fatigue in long-term breast carcinoma survivors: a longitudinal investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Fatigue and radiotherapy: (A) experience in patients undergoing treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Fatigue, depression and quality of life in cancer patients: how are they related?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Mechanisms of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Use of a case definition approach to identify cancer-related fatigue in women undergoing adjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Comparison between fatigue, sleep disturbance, and circadian rhythm in cancer inpatients and healthy volunteers: evaluation of diagnostic criteria for cancer-related fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Exercise reduces daily fatigue in women with breast cancer receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

A randomized controlled trial to evaluate the effectiveness of a brief, behaviorally oriented intervention for cancer-related fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Evidence-based treatment for cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Impact of epoetin beta on quality of life in patients with malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: results of a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Palliative Uses of Methylphenidate in Patients With Cancer: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Safety of anaemia drug erythropoietin is to be reviewed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJN250

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJN250

1 reference

19 August 2017

1 reference